In vivo chronic exposure to heroin or naltrexone selectively inhibits liver microsome formation of estradiol-3-glucuronide in the rat

Biochemical Pharmacology

Volumn 76, Issue 5, 2008, Pages 672-679

  Antonilli, Letizia ^a   Brusadin, Valentina ^b   Milella, Michele S ^a   Sobrero, Fabrizia ^a   Badiani, Aldo ^a   Nencini, Paolo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF BARI   (Italy)

Author keywords

Estradiol 17 glucuronide; Estradiol 3 glucuronide; Heroin; Naltrexone; UGT1A1

Indexed keywords

DIAMORPHINE; ESTRADIOL 3 GLUCURONIDE; GLUCURONIDE; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A1; ISOENZYME; NALTREXONE; SODIUM CHLORIDE; UDP GLUCURONOSYLTRANSFERASE 2B1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME KINETICS; GLUCURONIDATION; IN VIVO STUDY; LIVER MICROSOME; LONG TERM EXPOSURE; MALE; MICHAELIS MENTEN KINETICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; RAT;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ESTRADIOL; GLUCURONOSYLTRANSFERASE; HEROIN; MALE; MICROSOMES, LIVER; NALTREXONE; NARCOTIC ANTAGONISTS; NARCOTICS; POLYMERASE CHAIN REACTION; RATS; RATS, SPRAGUE-DAWLEY; SPECTROMETRY, FLUORESCENCE;

EID: 49149112859     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2008.06.011     Document Type: Article

References (38)

1. Milne R.W., Nation R.L., and Somogyi A.A. The disposition of morphine and its 3 and 6-glucuronide metabolites in humans and animals, and the importance of the metabolites to the pharmacological effects of morphine. Drug Metab Rev 28 (1996) 345-472
2. Kiang T.K., Ensom M.H., and Chang T.K. UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther 106 (2005) 97-132
3. Faura C.C., Collins S.L., Moore R.A., and Mcquay H.J. Systematic review of factors affecting the ratios of morphine and its major metabolites. Pain 74 (1998) 43-53
4. Hanna M.H., Elliott K.M., and Fung M. Randomized, double-blind study of the analgesic efficacy of morphine-6-glucuronide versus morphine sulfate for postoperative pain in major surgery. Anesthesiology 102 (2005) 815-821
5. Lotsch J., Zimmermann M., Darimont J., Marx C., Dudziak R., Skarke C., et al. Does the A118G polymorphism at the mu-opioid receptor gene protect against morphine-6-glucuronide toxicity?. Anesthesiology 97 (2002) 814-819
6. Lotsch J. Pharmacokinetic-pharmacodynamic modeling of opioids. J Pain Symptom Manage 29 5 Suppl. (2005) S90-S103
7. Skarke C., Geisslinger G., and Lötsch J. Is morphine-3-glucuronide of therapeutic relevance?. Pain 116 (2005) 177-180
8. Smith M.T. Neuroexcitatory effects of morphine and hydromorphone: evidence implicating the 3-glucuronide metabolites. Clin Exp Pharmacol Physiol 27 (2000) 524-528
9. Antonilli L., Semeraro F., Suriano C., Signore L., and Nencini P. High levels of morphine-6-glucuronide in street heroin addicts. Psychopharmacology (Berl) 170 (2003) 200-204
10. Antonilli L., Suriano C., Paolone G., Badiani A., and Nencini P. Repeated exposure to heroin and/or cadmium alter the rate of formation of morphine glucuronides in the rat. J Pharmacol Exp Ther 307 (2003) 651-660
11. Antonilli L., Petecchia E., Caprioli D., Badiani A., and Nencini P. Effect of repeated administrations of heroin, naltrexone, methadone and alcohol on morphine glucuronidation in the rat. Psychopharmacology 182 (2005) 52-64
12. Graziani M, Antonilli L, Togna T, Brusadin V, Viola S, Togna G, et al. Non-opioid induction of morphine-6-glucuronide synthesis is elicited by prolonged exposure of rat hepatocytes to heroin. Drug Alcohol Depend, 2008 Jun 30.
13. King C.D., Rios G.R., Green M.D., MacKenzie P.I., and Tephly T.R. Comparison of stably expressed rat UGT1.1 and UGT2B1 in the glucuronidation of opioid compounds. Drug Metab Dispos 25 (1997) 251-255
14. Ishii Y., Takami A., Tsuruda K., Kurogi A., Yamada H., and Oguri K. Induction of two UDP-glucuronosyltransferase isoforms sensitive to phenobarbital that are involved in morphine glucuronidation: production of isoform-selective antipeptide antibodies toward UGT1.1r and UGT2B1. Drug Metab Dispos 25 (1997) 163-167
15. Senafi S.B., Clarke D.J., and Burchell B. Investigation of the substrate specificity of a cloned expressed human bilirubin UDP-glucuronosyltransferase: UDP-sugar specificity and involvement in steroid and xenobiotic glucuronidation. Biochem J 303 Pt 1 (1994) 233-240
16. Williams J.A., Ring B.J., Cantrell V.E., Campanale K., Jones D.R., Hall S.D., et al. Differential modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1)-catalyzed estradiol-3-glucuronidation by the addition of UGT1A1 substrates and other compounds to human liver microsomes. Drug Metab Dispos 30 (2002) 1266-1273
17. Luquita M.G., Catania V.A., Pozzi E.J., Veggi L.M., Hoffman T., Pellegrino J.M., et al. Molecular basis of perinatal changes in UDP-glucuronosyltransferase activity in maternal rat liver. J Pharmacol Exp Ther 298 (2001) 49-56
18. Yu C., Ritter J.K., Krieg R.J., Rege B., Karnes T.H., and Sarkar M.A. Effect of chronic renal insufficiency on hepatic and renal udp-glucuronyltransferases in rats. Drug Metab Dispos 34 (2006) 621-627
19. Alkharfy K.M., and Frye R.F. Sensitive liquid chromatographic method using fluorescence detection for the determination of estradiol 3- and 17-glucuronides in rat and human liver microsomal incubations: formation kinetics. J Chromatogr B Analyt Technol Biomed Life Sci 774 (2002) 33-38
20. Palma E., Amici M., Sobrero F., Spinelli G., Di Angelantonio S., Ragozzino D., et al. Anomalous levels of Cl-transporters in the hippocampal subiculum from temporal lobe epilepsy patients make GABA excitatory. Proc Natl Acad Sci USA 103 (2006) 8465-8468
21. King C.D., Green M.D., Rios G.R., Coffman B.L., Owens I.S., Bishop W.P., et al. The glucuronidation of exogenous and endogenous compounds by stably expressed rat and human UDP-glucuronosyltransferase 1.1. Arch Biochem Biophys 332 (1996) 92-100
22. Tian H., Ou J., Strom S.C., and Venkataramanan R. Activity and expression of various isoforms of uridine diphosphate glucuronosyltransferase are differentially regulated during hepatic regeneration in rats. Pharm Res 22 (2005) 2007-2015
23. Fisher M.B., Campanale K., Ackermann B.L., VandenBranden M., and Wrighton S.A. In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin. Drug Metab Dispos 28 (2000) 560-566
24. Ghosh S.S., Sappal B.S., Kalpana G.V., Lee S.W., Chowdhury J.R., and Chowdhury N.R. Homodimerization of human bilirubin-uridine-diphosphoglucuronate glucuronosyltransferase-1 (UGT1A1) and its functional implications. J Biol Chem 276 (2001) 42108-42115
25. Pfeiffer E., Treiling C.R., Hoehle S.I., and Metzler M. Isoflavones modulate the glucuronidation of estradiol in human liver microsomes. Carcinogenesis 26 (2005) 2172-2178
26. Soars M.G., Petullo D.M., Eckstein J.A., Kasper S.C., and Wrighton S.A. An assessment of udp-glucuronosyltransferase induction using primary human hepatocytes. Drug Metab Dispos 32 (2004) 140-148
27. Mackenzie P.I., Gregory P.A., Gardner-Stephen D.A., Lewinsky R.H., Jorgensen B.R., Nishiyama T., et al. Regulation of UDP glucuronosyltransferase genes. Curr Drug Metab 4 (2003) 249-257
28. Ventura C., Zinellu E., Maninchedda E., and Maioli M. Dynorphin B is an agonist of nuclear opioid receptors coupling nuclear protein kinase C activation to the transcription of cardiogenic genes in GTR1 embryonic stem cells. Circ Res 92 (2003) 623-629
29. Shelby M.K., and Klaassen C.D. Induction of rat UDP-glucuronosyltransferases in liver and duodenum by microsomal enzyme inducers that activate various transcriptional pathways. Drug Metab Dispos 34 (2006) 1772-1778
30. Xie W., Yeuh M.F., Radominska-Pandya A., Saini S.P., Negishi Y., and Bottroff B.S. Control of steroid, heme, and carcinogen metabolism by nuclear pregnane X receptor and constitutive androstane receptor. Proc Natl Acad Sci USA 100 (2003) 4150-4155
31. Fujiwara R., Nakajima M., Yamanaka H., Katoh M., and Yokoi T. Interactions between human UGT1A1, UGT1A4, and UGT1A6 affect their enzymatic activities. Drug Metab Dispos 35 (2007) 1781-1787
32. Nakajima M., Yamanaka H., Fujiwara R., Katoh M., and Yokoi T. Stereoselective glucuronidation of 5-(4′-hydroxyphenyl)-5-phenylhydantoin by human UDP-glucuronosyltransferase (UGT) 1A1, UGT1A9, and UGT2B15: effects of UGT-UGT interactions. Drug Metab Dispos 35 (2007) 1679-1686
33. Takeda S., Ishii Y., Iwanaga M., Mackenzie P.I., Nagata K., Yamazoe Y., et al. Modulation of UDP-glucuronosyltransferase function by cytochrome P450: evidence for the alteration of UGT2B7-catalyzed glucuronidation of morphine by CYP3A4. Mol Pharmacol 67 (2005) 665-672
34. Takeda S., Kitajima Y., Ishii Y., Nishimura Y., Mackenzie P.I., Oguri K., et al. Inhibition of UDP-glucuronosyltransferase 2b7-catalyzed morphine glucuronidation by ketoconazole: dual mechanisms involving a novel noncompetitive mode. Drug Metab Dispos 34 (2006) 1277-1282
35. Ishii Y., Tsuruda K., Tanaka M., and Oguri K. Purification of a phenobarbital-inducible morphine UDP-glucuronyltransferase isoform, absent from Gunn rat liver. Arch Biochem Biophys 315 (1994) 345-351
36. Kim J.S., and Lemasters J.J. Opioid receptor-independent protection of ischemic rat hepatocytes by morphine. Biochem Biophys Res Commun 351 (2006) 958-964
37. Vassou D., Bakogeorgou E., Kampa M., Dimitriou H., Hatzoglou A., and Castanas E. Opioids modulate constitutive B-lymphocyte secretion. Int Immunopharmacol 8 (2008) 634-644
38. Wu H.E., Sun H.S., and Cheng C.W. Tseng LF. p38 mitogen-activated protein kinase inhibitor SB203580 reverses the antianalgesia induced by dextro-morphine or morphine in the mouse spinal cord. Eur J Pharmacol 550 (2006) 91-94